Full Speed Ahead Right Into The Iceberg

Quote

Anonymous

Guest
Hmmm, more negative results in Pomaglumetad Methionil Phase II trials, nearly the entire biotech and financial industry giving Solanezumab a <25% chance of winning approval, and one of the biggest, most spectacular epic failures in the history of Neuroscience with Semagacestat. David Bredt almost single handedly destroying an entire division (before he suddenly “left”), and John Lechleiter steadfastly committed to the “high-risk, high-reward” pipeline as the patent cliff gets ever higher and higher. I think the best article out there that describes this is “Lilly will sink if Solaneuzumab fails”. However, this is another great article to describe the situation:

http://www.mmm-online.com/lilly-pipeline-chokes-again-as-patent-experies-loom/article/249831/

One has to wonder, is if they are doing this on purpose, or are just that incompetent?
 


















Anonymous said:
Hmmm, more negative results in Pomaglumetad Methionil Phase II trials, nearly the entire biotech and financial industry giving Solanezumab a <25% chance of winning approval, and one of the biggest, most spectacular epic failures in the history of Neuroscience with Semagacestat. David Bredt almost single handedly destroying an entire division (before he suddenly “left”), and John Lechleiter steadfastly committed to the “high-risk, high-reward” pipeline as the patent cliff gets ever higher and higher. I think the best article out there that describes this is “Lilly will sink if Solaneuzumab fails”. However, this is another great article to describe the situation:

http://www.mmm-online.com/lilly-pipeline-chokes-again-as-patent-experies-loom/article/249831/

One has to wonder, is if they are doing this on purpose, or are just that incompetent?
Click to expand...

Saw this on CBS News. It's about a Lilly competitor's research scientist who discovered she has Alheimer's and volunteered for her company's monoclonal antibody trial. She says it's not slowing things down for her unfortunately. Hopefully the Lilly Mab performs better but I'd put the odds of success <5%.

http://www.cbsnews.com/8301-18563_162-57470627/an-alzheimers-researcher-who-is-also-a-patient/
 






Anonymous said:
Hmmm, more negative results in Pomaglumetad Methionil Phase II trials, nearly the entire biotech and financial industry giving Solanezumab a <25% chance of winning approval, and one of the biggest, most spectacular epic failures in the history of Neuroscience with Semagacestat. David Bredt almost single handedly destroying an entire division (before he suddenly “left”), and John Lechleiter steadfastly committed to the “high-risk, high-reward” pipeline as the patent cliff gets ever higher and higher. I think the best article out there that describes this is “Lilly will sink if Solaneuzumab fails”. However, this is another great article to describe the situation:

http://www.mmm-online.com/lilly-pipeline-chokes-again-as-patent-experies-loom/article/249831/

One has to wonder, is if they are doing this on purpose, or are just that incompetent?
Click to expand...


Our two new hot molecules don't have a chance of making it to the market.... Romney has better odds of making it to the White House. Our investigators and Senior Leaders know the truth-
 












Anonymous said:
Our two new hot molecules don't have a chance of making it to the market.... Romney has better odds of making it to the White House. Our investigators and Senior Leaders know the truth-
Click to expand...

The mission here is only to mis-lead the shareholders long enough for our senior leaders to squeeze out one more multi-million dollar bonus. It's not about Lilly's future, it's about their retirement.
 
















































Bapi just went down in flames. Are we all excited to see solanezumab see the same fate?

Let's just hope that Lilly acts like Pfizer and waits until 5:15 pm AFTER the stock market closes to release the negative data. That way, all the people with lots of stock can dump it off-hours. We can't have any important people lose money now, can we?


http://www.pharmalot.com/2012/08/bapi-is-a-bust-pfizer-jj-alzheimer-med-fails/
 


















Top Bottom
Back
Quote